小狗阅读会员会员
医学顶刊SCI精读工具

扫码登录小狗阅读

阅读SCI医学文献
Document
订阅泛读方向 订阅泛读期刊
  • 我的关注
  • 我的关注
  • {{item.title}}

    按需关注领域/方向,精准获取前沿热点

  • {{item.title}}

    {{item.follow}}人关注

  • {{item.subscribe_count}}人订阅

    IF:{{item.impact_factor}}

    {{item.title}}

Association of hypokalemia with cortisol and ACTH levels in Cushing's disease.

库欣病低钾血症与皮质醇和ACTH水平的相关性。

  • 影响因子:4.46
  • DOI:10.1111/nyas.14205
  • 作者列表:"Fan L","Zhuang Y","Wang Y","Liu X","Liu D","Xiang B","He M","Zhang Z","Li Y","Wang Y","Zhu X","Ye H
  • 发表时间:2020-03-01
Abstract

:Hypokalemia is a common feature in patients with Cushing's syndrome (CS). Whether the occurrence of hypokalemia is associated with cortisol and adrenocorticotropic hormone (ACTH) levels is still unclear. Approximately 80% of cases of endogenous CS are due to Cushing's disease (CD). The purpose of this study was to determine the association of hypokalemia with cortisol and ACTH levels in patients with CD. The retrospective study included 195 patients with CD referred to our medical center from January 2011 to December 2017. The results show that 25.64% (50/195) of the patients had hypokalemia. The 24-h urinary free cortisol (UFC) and plasma cortisol levels were significantly higher in patients with hypokalemia than those with normokalemia (P < 0.05). Plasma ACTH levels were similar between the patients with hypokalemia and normokalemia (P > 0.05). Cortisol levels were negatively correlated with plasma potassium levels (08:00: r = -0.344 (P < 0.01), 00:00: r = -0.435 (P < 0.01); 24-h UFC: r = -0.281 (P < 0.05)). There was no significant correlation between the plasma ACTH and potassium (08:00: r = -0.093 (P > 0.05), 00:00: r = -0.184 (P > 0.050)). Our current data suggest that cortisol level, instead of ACTH level, is correlated with plasma potassium level. A high cortisol level may be the principal cause of hypokalemia.

摘要

: 低钾血症是库欣综合征 (CS) 患者的常见特征。低钾血症的发生是否与皮质醇和促肾上腺皮质激素 (ACTH) 水平有关尚不清楚。大约 80% 的内源性CS病例是由库欣病 (CD) 引起的。本研究的目的是确定CD患者低钾血症与皮质醇和ACTH水平的关系。回顾性研究纳入了 2011 年 1 月至 2017 年 12 月转诊至本医学中心的 195 例CD患者。结果显示,25.64% (50/195) 的患者有低钾血症。低钾血症患者 24 h尿游离皮质醇 (UFC) 和血浆皮质醇水平明显高于正常血钾者 (P <0.05)。低钾血症和正常血钾患者血浆ACTH水平相似 (P> 0.05)。皮质醇水平与血浆钾水平呈负相关 (08:00: r = -0.344 (P <0.01),00:00: r = -0.435 (P < 0.01); 24-h UFC: r = -0.281 (P <0.05))。血浆ACTH与血钾无明显相关性 (08:00: r = -0.093 (P> 0.05),00:00: r = -0.184 (P> 0.050)。我们目前的数据表明,皮质醇水平,而不是ACTH水平,与血浆钾水平相关。高皮质醇水平可能是低钾血症的主要原因。

下载该文献
小狗阅读

帮助医生、学生、科研工作者解决SCI文献找不到、看不懂、阅读效率低的问题。提供领域精准的SCI文献,通过多角度解析提高文献阅读效率,从而使用户获得有价值研究思路。

相关文献
影响因子:2.62
发表时间:2020-02-01
来源期刊:Surgery
DOI:10.1016/j.surg.2019.05.024
作者列表:["Prendergast KM","Smith PM","Tran TB","Postlewait LM","Maithel SK","Prescott JD","Pawlik TM","Wang TS","Glenn J","Hatzaras I","Shenoy R","Phay JE","Shirley LA","Fields RC","Jin LX","Weber SM","Salem A","Sicklick JK","Gad S","Yopp AC","Mansour JC","Duh QY","Seiser N","Votanopoulos KI","Levine EA","Poultsides GA","Solórzano CC","Kiernan CM"]

METHODS:BACKGROUND:Adrenocortical carcinoma is a rare, aggressive cancer. We compared features of patients who underwent synchronous versus metachronous metastasectomy. METHODS:Adult patients who underwent resection for metastatic adrenocortical carcinoma from 1993 to 2014 at 13 institutions of the US adrenocortical carcinoma group were analyzed retrospectively. Patients were categorized as synchronous if they underwent metastasectomy at the index adrenalectomy or metachronous if they underwent resection after recurrence of the disease. Factors associated with overall survival were assessed by univariate analysis. RESULTS:In the study, 84 patients with adrenocortical carcinoma underwent metastasectomy; 26 (31%) were synchronous and 58 (69%) were metachronous. Demographics were similar between groups. The synchronous group had more T4 tumors at the index resection (42 vs 3%, P < .001). The metachronous group had prolonged median survival after the index resection (86.3 vs 17.3 months, P < .001) and metastasectomy (36.9 vs 17.3 months, P = .007). Synchronous patients with R0 resections had improved survival compared to patients with R1/2 resections (P = .008). Margin status at metachronous metastasectomy was not associated with survival (P = .452). CONCLUSION:Select patients with metastatic adrenocortical carcinoma may benefit from metastasectomy. Patients with metachronous metastasectomy have a more durable survival benefit than those undergoing synchronous metastasectomy. This study highlights need for future studies examining differences in tumor biology that could explain outcome disparities in these distinct patient populations.

关键词: 暂无
翻译标题与摘要 下载文献
影响因子:4.46
发表时间:2020-03-01
DOI:10.1111/nyas.14205
作者列表:["Fan L","Zhuang Y","Wang Y","Liu X","Liu D","Xiang B","He M","Zhang Z","Li Y","Wang Y","Zhu X","Ye H"]

METHODS::Hypokalemia is a common feature in patients with Cushing's syndrome (CS). Whether the occurrence of hypokalemia is associated with cortisol and adrenocorticotropic hormone (ACTH) levels is still unclear. Approximately 80% of cases of endogenous CS are due to Cushing's disease (CD). The purpose of this study was to determine the association of hypokalemia with cortisol and ACTH levels in patients with CD. The retrospective study included 195 patients with CD referred to our medical center from January 2011 to December 2017. The results show that 25.64% (50/195) of the patients had hypokalemia. The 24-h urinary free cortisol (UFC) and plasma cortisol levels were significantly higher in patients with hypokalemia than those with normokalemia (P < 0.05). Plasma ACTH levels were similar between the patients with hypokalemia and normokalemia (P > 0.05). Cortisol levels were negatively correlated with plasma potassium levels (08:00: r = -0.344 (P < 0.01), 00:00: r = -0.435 (P < 0.01); 24-h UFC: r = -0.281 (P < 0.05)). There was no significant correlation between the plasma ACTH and potassium (08:00: r = -0.093 (P > 0.05), 00:00: r = -0.184 (P > 0.050)). Our current data suggest that cortisol level, instead of ACTH level, is correlated with plasma potassium level. A high cortisol level may be the principal cause of hypokalemia.

翻译标题与摘要 下载文献
影响因子:6.93
发表时间:2020-04-15
DOI:10.1002/ijc.32654
作者列表:["Ghosal S","Das S","Pang Y","Gonzales MK","Huynh TT","Yang Y","Taieb D","Crona J","Shankavaram UT","Pacak K"]

METHODS::Many long intergenic noncoding RNAs (lincRNAs) serve as cancer biomarkers for diagnosis or prognostication. To understand the role of lincRNAs in the rare neuroendocrine tumors pheochromocytoma and paraganglioma (PCPG), we performed first time in-depth characterization of lincRNA expression profiles and correlated findings to clinical outcomes of the disease. RNA-Seq data from patients with PCPGs and 17 other tumor types from The Cancer Genome Atlas and other published sources were obtained. Differential expression analysis and a machine-learning model were used to identify transcripts specific to PCPGs, as well as established PCPG molecular subtypes. Similarly, lincRNAs specific to aggressive PCPGs were identified, and univariate and multivariate analysis was performed for metastasis-free survival. The results were validated in independent samples using RT-PCR. From a pan-cancer context, PCPGs had a specific and unique lincRNA profile. Among PCPGs, five different molecular subtypes were identified corresponding to the established molecular classification. Upregulation of 13 lincRNAs was found to be associated with aggressive/metastatic PCPGs. RT-PCR validation confirmed the overexpression of four lincRNAs in metastatic compared to non-metastatic PCPGs. Kaplan-Meier analysis identified five lincRNAs as prognostic markers for metastasis-free survival of patients in three subtypes of PCPGs. Stratification of PCPG patients with a risk-score formulated using multivariate analysis of lincRNA expression profiles, presence of key driver mutations, tumor location, and hormone secretion profiles showed significant differences in metastasis-free survival. PCPGs thus exhibit a specific lincRNA expression profile that also corresponds to the established molecular subgroups and can be potential marker for the aggressive/metastatic PCPGs.

翻译标题与摘要 下载文献
肾上腺疾病方向

主要包括肾上腺皮质疾病、肾上腺肿瘤、先天性肾上腺增生、肾上腺机能不全、肾上腺皮质机能亢进等疾病。

复制标题
发送后即可在该邮箱或我的下载查看该文献
发送
该文献默认存储到我的下载

科研福利

临床科研之家订阅号

报名咨询

建议反馈
问题标题:
联系方式:
电子邮件:
您的需求: